AL Amyloidosis Clinical Trials

73 clinical trials for AL Amyloidosis across international registries, including 25 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). — RECRUITING · PHASE2
• Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis — RECRUITING · PHASE2
• The Norwegian Immunotherapy in Multiple Myeloma Study — RECRUITING
• Hungarian National Systemic Amyloidosis Registry — RECRUITING
• Optimize First-line Treatment for AL Amyloidosis With t (11; 14) — RECRUITING · NA
• Evaluation of Skin Tests in Biotherapy Allergies — RECRUITING · NA
• Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis — RECRUITING · PHASE1
• Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis — RECRUITING · PHASE1
• Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis — RECRUITING · PHASE3
• One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS — RECRUITING
• A Registry of AL Amyloidosis (ReAL) — RECRUITING
• Promoting Diagnosis and Management of AL in Italy (ProDigALIty) — RECRUITING
• A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) — RECRUITING
• Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial — RECRUITING · PHASE2
• Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource — RECRUITING
• Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis — RECRUITING · PHASE1
• Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment — RECRUITING
• BE.Amycon Biobank & Data Registry UZ Leuven — RECRUITING
• Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis — RECRUITING
• Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research — RECRUITING · PHASE1
• Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis — RECRUITING · PHASE2
• Teclistamab in Previously Treated AL Amyloidosis — RECRUITING · PHASE2
• Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis — RECRUITING · NA
• Autologous Stem Cell Transplantation for Patients With AL Amyloidosis — RECRUITING
• National Registry of Rare Kidney Diseases — RECRUITING
• A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis — COMPLETED · PHASE3
• BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) — NOT_YET_RECRUITING · PHASE2
• Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis — COMPLETED · PHASE3
• A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis — COMPLETED · PHASE2
• A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE2
• Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE1
• Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) — ACTIVE_NOT_RECRUITING · PHASE3
• Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging — NOT_YET_RECRUITING · NA
• A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement — NOT_YET_RECRUITING · PHASE1
• Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance — COMPLETED
• BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy — WITHDRAWN · NA
• Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis — COMPLETED · NA
• Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis — COMPLETED
• Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders — COMPLETED · NA
• Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab — ACTIVE_NOT_RECRUITING · PHASE2
• A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy — OTHER · PHASE2
• Ixazomib Maintenance Study in Patients With AL Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE2
• Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis — NOT_YET_RECRUITING · PHASE2
• Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) — WITHDRAWN · PHASE1
• A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis — COMPLETED · PHASE2
• Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis — TERMINATED · PHASE2
• Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis — COMPLETED · PHASE1

Refine this search